<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204593</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_R_05033</org_study_id>
    <secondary_id>U1111-1116-3450</secondary_id>
    <nct_id>NCT01204593</nct_id>
  </id_info>
  <brief_title>baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus</brief_title>
  <acronym>SUBSTITUTE</acronym>
  <official_title>Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day,
      tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type
      1 Diabetes Mellitus (T1DM).

      Secondary Objectives:

      To evaluate:

        -  The change of hemoglobin A1c (HbA1c) from baseline to week 12

        -  The percentage of patients with HbA1c &lt; 7% at week 12 and week 24

        -  The FBG and the 7-point self monitoring of blood glucose (SMBG) at baseline, week 12 and
           week 24

        -  The daily dose for both insulin glulisine insulin glargine at baseline, week 12 and week
           24

        -  The incidence of symptomatic hypoglycemias

        -  Adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a two-week run-in period patients will enter a six-month treatment period.

      Estimated study duration per patient : 26 weeks (including a 2-week run-in period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))</measure>
    <time_frame>between baseline (week 0) and endpoint (week 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>from baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c &lt; 7%</measure>
    <time_frame>at week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose (FBG)</measure>
    <time_frame>at baseline, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Self Monitoring of Blood Glucose (SMBG)</measure>
    <time_frame>at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dose for insulin glulisine</measure>
    <time_frame>At baseline, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dose for insulin glargine</measure>
    <time_frame>At baseline, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hypoglycemias</measure>
    <time_frame>From baseline (week 0) to endpoint (week 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).
Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) &lt; 180 mg/dL (&lt;10.0 mmol/L) and ideally around 140 mg/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime</description>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <other_name>Lantus SoloStar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal</description>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <other_name>Apidra SoloStar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Known Type 1 diabetic patients (male or female) treated with any type of insulin
             regimen, except:

               -  continuous subcutaneous insulin infusion (CSII, or pump), and

               -  patients already treated with insulin glargine

          2. Age: 18-60 years inclusive

          3. HbA1c: 8% - 10% assessed over the past 6 month

          4. At least 1 year of continuous insulin treatment

          5. Willingness to accept, and ability to follow:

               -  a basal bolus regimen (glargine x1 and glulisine x3 per day),

               -  self-monitoring blood glucose (SMBG)

               -  a fixed meal plan, or CHO counting

          6. Signed informed consent obtained prior to any study procedure

        Criteria for entry in the treatment period:

          1. HbA1c 8-10% assessed between week -2 and week 0

          2. Serum creatinine ≤135 micromol/L in men and ≤110 micromol/L in women

          3. Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) lower or equal
             to three times the upper limit of normal

          4. Pregnancy test negative if women of childbearing potential

        Exclusion criteria:

          1. History of hypersensitivity to insulin glargine and/or insulin glulisine

          2. Pregnant, breast-feeding or women of childbearing potential not using efficient
             contraception

          3. Brittle diabetes

          4. Known impaired renal function defined as serum creatinine &gt; 135 micromol/L in men and
             &gt; 110 micromol/L in women at study entry

          5. Known impaired hepatic function defined as Alanine aminotransferase (ALT) and/or
             Aspartate aminotransferase (AST) greater than three times the upper limit of normal at
             study entry

          6. Diabetes ketoacidosis

          7. History of drug or alcohol abuse

          8. Psychiatric or mental disease

          9. Inclusion in another study in the past 6 months or previous inclusion in this study

         10. Patient unable or unwilling to manage properly the basal bolus regimen

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 01201</name>
      <address>
        <city>Algeries</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 01202</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 01203</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 01204</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03201</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03202</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03203</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03204</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 03205</name>
      <address>
        <city>Morón</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-007</name>
      <address>
        <city>Curitiba</city>
        <zip>80540-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-003</name>
      <address>
        <city>Distrito Federal</city>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-010</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-006</name>
      <address>
        <city>Marília</city>
        <zip>17519-101</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-004</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-002</name>
      <address>
        <city>São Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17003</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17004</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17005</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17007</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 17006</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 01</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 48401</name>
      <address>
        <city>Guadalajara</city>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 48402</name>
      <address>
        <city>Guadalajara</city>
        <zip>44656</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 48404</name>
      <address>
        <city>Guadalajara</city>
        <zip>44680</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 48403</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1</name>
      <address>
        <city>Riyadh</city>
        <zip>11415</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12468</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710004</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12466</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710006</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12464</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12465</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710001</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710002</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12484</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710003</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12467</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710005</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 78801</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 78805</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 78803</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 78802</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 78804</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Kuwait</country>
    <country>Mexico</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

